Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Crest Nicholson Woes Topple Housebuilders

Tue, 12th Jun 2018 10:52

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Centrica, up 2.1%. Jefferies raised the energy services company to a Buy rating from Hold and also increased its target price to 165 pence from 140p.----------Reckitt Benckiser, up 1.6%. Credit Suisse upped the health and hygiene products manufacturer to 5,500 pence from 5,450p, retaining its Underperform rating.----------FTSE 100 - LOSERS----------Barratt Developments, down 2.2%, Berkeley Group Holdings, down 2.1%, Persimmon, down 1.4% and Taylor Wimpey, down 1.4%. Blue chip housebuilders fell to the bottom of the index after FTSE 250-listed Crest Nicholson reported drop in first half margins and warned annual margins will be at the bottom end of its guidance range.----------FTSE 250 - WINNERS----------IMI, up 2.5%. Morgan Stanley upped the engineering firm to an Overweight rating from Equal Weight, and raised its price target to 1,410 pence from 1,180p.----------Greencore Group, up 0.8%. Numis raised the sandwich maker to an Add rating from Hold, along with the price target to 210 pence from 138p.----------Fidelity China Special Situations, up 1.2%. Although the China-focused investment trust had a net asset value total return of 22.2%, underperforming the MSCI China Index which returned 23.6% for the year to the end of March, Fidelity reported a substantial rise in net asset value per share at 272.55 pence as at March 31, up from 225.36p on the same date the year before. In addition, the trust declared a final dividend of 3.50 pence, up 40% from 2.50p the year before.----------FTSE 250 - LOSERS----------Crest Nicholson Holdings, down 5.9%. The housebuilder reported a 2% drop in pretax profit for the six months ended April 30 to GBP74.8 million from GBP76.2 million year-on-year. Headline gross margins for the period were at 23.6%, down from 26.3% the prior year due to flat pricing amid a backdrop of build cost inflation at 3% to 4%. Crest Nicholson said it expects operating margins for the full year at around 18%, lower compared to last year at 20.3%. This is at the bottom range of Crest Nicholson's guidance range of 18% to 20%.----------Domino's Pizza Group, down 5.5%. The pizza retailer reported the resignation of Chief Financial Officer and board member Rachel Osborne and said that it has commenced a search for her successor. Osborne's resignation was effective from Monday and the company did not give any specific details regarding her departure. The pizza retailer also reiterated its earnings outlook given in March and remains confidence regarding its performance in 2018 and beyond.----------Ted Baker, down 3.6%. The lifestyle group for the 19-week period from January 28 to June 9 reported revenue increase by 4.2% compared with the same period a year ago. "This performance was achieved despite the impact of unseasonal weather across Europe and the East Coast of America in the early part of the period and, as previously reported, external trading conditions remaining challenging across many of our global markets," the company said. Total retail sales for the period increased by 0.7%, with e-commerce sales up 34%.----------OTHER MAIN MARKET AND AIM - WINNERS----------Clear Leisure, up 11%. The leisure sector investment company reached a settlement agreement with Peter McBride regarding an interest on a loan the company owed him. The settlement is in regard to an amount of GBP91,722 relating to interest accrued on a loan of GBP250,000 made by Square One Ltd to Clear Leisure in March 2015. Settlement will be reached through the issue and allotment of 8.3 million shares at 1.11 pence each. Square One assigned the benefit of the interest to McBride in February.----------OTHER MAIN MARKET AND AIM - LOSERS----------Stratex International, down 16%. The gold exploration company said it entered a conditional option agreement with Bureau d'Etudes et d'Investigations Geologico-minieres, Geotechniques et Geophysiques SARL, for its two early stage projects Bibemi and Wapouze in north Cameroon. Stratex will manage the project, while Bureau provides consulting and operational support. In addition, to support the placing, Stratex intends to raise GBP1 million through a placing of shares at the expected price of 0.5 pence per share. ----------IXICO, down 10%. The clinical trial data management services provider announced the cessation of a trial of an Alzheimer's disease treatment. IXICO didn't state whether or not the treatment in question was AstraZeneca's lanabecestat, for which the phase three trials have been discontinued. IXICO was providing specialist imaging clinical trial services for the trial. The USD7.7 million contract for the clinical trial was secured in September 2017 by IXICO and was scheduled to end in 2024. Over the past three years, IXICO recognised USD2.0 million from the contract. The termination of the trial is not expected to materially impact the company's performance and IXICO remains on track to generating revenue in excess of GBP4.5 million and meet market expectations for the current financial year.----------
More News
17 Jan 2017 08:47

Giulio Cerroni appointed CEO of IXICO

(ShareCast News) - Brain health company IXICO announced on Tuesday that Giulio Cerroni will be appointed to the board as chief executive officer, with effect from 6 February. The AIM-traded firm said Derek Hill, the co-founder and current CEO, will remain on the board and continue to serve as an exe

Read more
16 Nov 2016 10:01

Ixico joins European syndicate to collect data on Alzheimer's

(ShareCast News) - Brain health company Ixico is to receive €100,000 to provide digital technologies for collection and analysis of data , which further expands its work on wearable bio-sensors as part of a pan-European partnership. The AIM-listed company is to participate in a new collaborative EU

Read more
21 Oct 2016 10:15

Ixico's income falls slightly but has a number of contracts in the pipeline

(ShareCast News) - AIM-listed Ixico's income for the year fell, but the brain health company has a number of contracts with pharmaceuticals in the pipeline and a "strong" balance sheet. In trading update for the year ended 30 September, the company reported revenues of £3.1m and other income of £700

Read more
20 Oct 2016 11:01

Ixico pens deal to help develop a therapy for Parkinson's like diesease

(ShareCast News) - Shares in AIM-listed Ixico rose above 22% on Thursday, as the brain health company announced it had signed a $1.2m contract with a global pharmaceutical for imaging clinical trial services for a Parkinson's-like neurodegenerative disease. The project is for a second phase clinical

Read more
10 Oct 2016 12:26

Ixico to receive €1m from EU Alzheimer's project

(ShareCast News) - AIM-listed pharmaceutical Ixico is to receive €1m as a partner in an EU public-private consortium, which has the potential for long-term revenue through the development of diagnostic and disease management technologies for Alzheimer's. Ixico is to work on the Amyloid Imaging to Pr

Read more
2 Jun 2016 16:27

IXICO study joins Dementias Platform

(ShareCast News) - Brain health company IXICO announced on Thursday that its Cygnus study has joined the high-profile Dementias Platform UK (DPUK). The AIM-traded firm described Cygnus as a real-world digital data collection study from people with cognitive impairment and dementia. It said the four

Read more
18 Jan 2016 13:51

Ixico wins four new contracts worth over £3m

(ShareCast News) - Brain health company Ixico was recently awarded four new contracts with "leading" pharmaceutical groups and a specialist biotechnology firm totalling over £3m in value. The contracts involve global clinical trials of novel drugs for Alzheimer's disease spanning three major phases

Read more
19 Oct 2015 12:33

Ixico full-year income in line with expectations

(ShareCast News) - Brain health company Ixico reported revenues for the year of £3.1m and other income at £1m, in line with market expectations and giving a total combined income of £4.1m. This was down from £4.3m for the 16-month period to 30 September 2014. In a pre-close trading update ahead of

Read more
29 Jun 2015 11:11

Ixico secures two clinical trial contracts alongside partner VirtualScopics

Ixico has won two contracts to deploy its products in unnamed pharmaceutical companies' clinical trials, alongside its partner VirtualScopics. Both studies will employ Ixico's TrialTracker digital platform to collect and image data, one pertaining to metastatic solid tumours and the other to rare ne

Read more
17 Sep 2014 08:48

IXICO Appoints CFO For October 1 Start

Read more
21 Jul 2014 15:45

DIRECTOR DEALINGS: IXICO Divisional Vice-President Buys Shares

Read more
18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Read more
19 Jun 2014 10:40

IXICO Joins Medical Research Council Collaboration For Dementia Drive

LONDON (Alliance News) - IXICO PLC said Thursday it will take part in a GBP16 million collaboration launched by publicly funded government agency the Medical Research Council to speed up research into dementia. The MRC has launched the UK Dementias Research Platform with the aim of seeking

Read more
19 Jun 2014 08:30

Ixico partners with the Medical Research Council to launch UK Dementias Research Platform

Biotechnology group Ixico has partnered with the Medical Research Council (MRC) to launch the UK Dementias Research Platform (UKDP), a £16m public-private partnership. The group, which set up the partnership to speed up research into dementias, will act as the MRC's imaging partner on the project a

Read more
6 Jun 2014 09:20

IXICO To Meet Full-Year Expectations As Interim Hit By Listing Costs

LONDON (Alliance News) - IXICO PLC expressed confidence Friday in meeting market expectations for the full year, as it swung into a loss in the half year to end-March, hit by costs relating to its AIM listing and a decline in revenues. The company was formed via the reverse takeover of Phyt

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.